Zymeworks Reports Phase 1 ZW191 Data in Ovarian Cancer
Phase 1 randomized data showed a 64.5% cORR at 6.4 mg/kg versus 55.3% at 9.6 mg/kg, with fewer grade ≥3 adverse events at 6.4 mg/kg. Responses spanned high to low or negative FRα expression.
Zymeworks reported randomized Phase 1 data for its FRα antibody-drug conjugate ZW191 in platinum-resistant ovarian cancer. The confirmed objective response rate was 64.5% at 6.4 mg/kg and 55.3% at 9.6 mg/kg. Fewer grade ≥3 adverse events were reported at 6.4 mg/kg. Responses were observed across high to low or negative FRα expression.